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Background: The new TomoDirect™ modality offers a non-rotational option with discrete beam angles. We have
investigated this mode for TBI with the intention to test the feasibility and to establish it as a clinical routine
method. Special foci were directed onto treatment planning, dosimetric accuracy and practical aspects.
Patients and methods: TBI plans were calculated with TomoDirect™ for a Rando™ phantom and all patients with
an intended fractionated total body irradiation between November 2013 and May 2014 (n = 8). Finally, four of these
patients were irradiated with TomoDirect™. Additionally we studied variations in the modulation factor, pitch, field
width of Y-jaws and dose grid during optimization. Dose measurements were performed using thermoluminescent
rods in the Rando™ phantom, with the Delta4® and with ionization chambers in a solid water phantom.
Results: For all eight calculated plans with a prescribed dose of 12 Gy Dmean was 12.09-12.33 Gy (12,25 ± 0.08 Gy),
D98 11.2-11.6 Gy (11.45 ± 0.12 Gy) and D2 12.6-13.1 Gy (12.94 ± 0.13 Gy). Dmean of inner lungs was 8.73 ± 0.22 Gy
on the left side and 8.69 ± 0.27 Gy on the right side.
When single planning parameters are varied with otherwise constant parameters, the modulation factor showed
the greatest impact on dose homogeneity and treatment time. The impact of the pitch was marginally, and almost
equal homogeneity can be obtained with field width of Y-jaws 5 cm and 2.5 cm.
Measurements with thermoluminescent rods (n = 25) in the Rando™ phantom showed a mean dose deviation
between measured and calculated dose of 0.66 ± 2.26%. 18 of 25 TLDs had a deviation below 3%, seven of 25 TLDs
between 3% and 5%.
Conclusion: TBI with TomoDirect™ allows a superior homogeneity compared to conventional methods, where lung
blocks are widely accepted. The treatment is performed only in supine position and is robust and comfortable for
the patient.
TomoDirect™ allows the implementation of organ-specific dose prescriptions. So the discussion about the balance
between the need for aggressive treatment and limited toxicity can be renewed with the new potentials of
TomoDirect™ - for children as well as for adults – and possibly yield a better clinical outcome in the future.
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Total body irradiations (TBI) are a special challenge
for treatment planning and dose application. The large
target size hampers the use of modern methods of radio-
oncology, like IMRT. Therefore conventional methods
are widely used, such as treatments with large source-
surface distances, arc techniques [1,2] and translational
methods [3,4]. Most of the current methods follow the* Correspondence: henning.salz@med.uni-jena.de
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and Marrow Transplantation (EBMT) [5], which suggest
to check the dose homogeneity along the patient’s midline
at several points and which specify the lung dose at a
point which is representative for more than 50% of the
lung volume. The use of physical blocks to reduce dose to
the lung, which includes lower dose under the blocks, is
widely accepted.
In recent years some TBI techniques such as arc tech-
niques have been enhanced [6,7]. According [7], the use
of an inverse optimization algorithm improves the doseis is an Open Access article distributed under the terms of the Creative
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planned arc techniques. There, the achieved percentage
of the PTV which received 90-110% of the prescribed
dose was 75.8-90.2% (n = 4). With these arc techniques
TBI can be performed even in normal treatment rooms.
The TomoTherapy® system (Accuray Inc., Sunnyvale,
USA) overcomes the geometrical limitations of classical
accelerators and allows the use of the advantages of
IMRT even for total body irradiation. First experiences
using the helical delivery mode have already been re-
ported by other groups [8-10]. Using this technique,
Gruen et al. reported an average dose received by 95% of
the target (D95%) for all patients (n = 10) of 11.7 Gy for a
prescription dose of 12Gy [9]. With the new TomoDirect™
modality, TomoTherapy® offers a non-rotational option
with discrete beam angles. This method is different in
some aspects from the helical mode. The dose is applied
through maximum twelve fixed beams, while the table is
moved through to the gantry. So it is comparable with an
IMRT with very large field lengths. First studies showed
that TomoDirect™ might be an efficient means to deliver
radiation at static angles for different indications [11,12],
and for craniospinal irradiation it is recommended [13]. In
our department this method is not used as an alternative
to the linac-based IMRT except for cases with very large
target volumes.
TomoDirect™ has the potential to improve TBI even in
comparison with the helical mode: (I) Because of the fact
that multiple fields are used, the treatment time from
the beginning to the end of the irradiation of the lung is
extended, which has the potential to decrease the risk of
interstitial pneumonitis. (II) TomoDirect™ allows a beam
expansion on both edges by a maximum of 5 leaves each
(3.125 cm at isocenter). This allows to ensure a sufficient
dose distribution even in the case of dislocations up to
2 cm of the surface.
We have investigated the TomoDirect™ mode for TBI
with the intention to test its feasibility and to establish it in
clinical routine for children as well as for adults even with
higher body mass indexes (BMI). Special foci were directed
onto treatment planning, dosimetric accuracy and practical
aspects. This work describes the new method and the re-
sults in detail and discusses differences to helical tomother-
apy and to our previous translational method with lung
blocks as well.
Materials and methods
Patient selection and dose prescription
All patients (7 adults, one child) with an intended TBI be-
tween November 2013 and April 2014 (n = 8) underwent
the planning process for TomoDirect™ to assess the feasi-
bility. Two of them were finally treated with the conven-
tional translational technique, four with TomoDirect™,
and two were not irradiated because of changing clinicalconditions. Detailed characteristics of the patient selection
are shown in Table 1.
The prescribed dose for the total body was 12 Gy, the
dose per fraction was 2 Gy for children (twice a day) and
3 Gy for adults (one fraction per day). The prescribed
total lung dose was 8 Gy.
Immobilization and planning CT
Patients were immobilized in supine position in a vac-
uum cushion (UNGER Medizintechnik GmbH&Co KG).
Masks for head and neck fixation were not used. CTs were
performed at a wide-bore CT scanner Optima CT580W
(General Electric). Two CT scans (one head-first, one feet-
first) were necessary for patients taller than 1.45 m be-
cause of limited table motion capacities of the CT and
TomoTherapy®.
Contouring
Contouring was performed with Oncentra® (Elekta AB),
treatment planning was performed with TomoHD™,
Version 1.2.1. The following structures were created: outer
body contour, planning target volume (PTV) consisting of
body without skin (distance to the surface 5 mm), eyes,
spinal cord, lung and central lung (distance to thoracic wall
10 mm for adults). Additionally, a help target structure
was defined which consisted of the PTV, a small connec-
tion of the left and the right leg and a safety margin near
the shoulder and superior of the head. If the irradiation
was split into a head-first and a feet-first part, two “overlap
regions” covering a length of 3 cm each were added be-
yond the PTVs. The upper overlap region should obtain
2/3 of the prescribed dose from the head-first plan and 1/
3 from the feet-first plan, the lower one 1/3 from the
head-first plan and 2/3 from the feet-first plan. By this a
gradual dose gradient was created to minimize the risk of
over- or underdosage by misplacement.
Treatment planning
The treatment planning was performed on the TomoTherapy®
planning station. The defined targets were in the order of
their priority settings in the inverse planning (1 = highest
priority): (1) left eye, (2) right eye, (3) spinal cord, (4) total
body, (5) left inner lung, (6) right inner lung, (7) “overlap
8 Gy”, (8) “overlap 4 Gy”, (9) second target (with the con-
nection between leg contours). Table 2 shows the con-
straints which have to be fulfilled. Additionally a sufficient
dose on the skin is also demanded.
Due to the technical limitation of the TomoTherapy®
table the possible table motion in long direction depends
on the table height. Therefore the table height was se-
lected (I) high enough to encompass the complete thorax
contour in the scan and (II) low enough to allow a large
table motion range.
Table 1 Patient characteristics
Patient no. Age (years) Sex Diagnosis Body length (cm) Body weight (kg) Body mass index (kg/m2) Used treatment technique
1 40 f ALL recurrence 176 70 22.6 translational technique
2 48 m ALL 188 116 32.8 translational technique
3 5 f ALL recurrence 104 18,3 16.9 TomoDirect
4 34 m AML 174 85 28.1 TomoDirect
5 41 m ALL 172 65 22.0 not treated
6 52 m AML 175 97 31.7 TomoDirect
7 33 f AML 172 85 28.7 not treated
8 37 m AML 185 77 22.5 TomoDirect
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with equally spaced angles were used for the head-first-plan
(see Figure 1), four fields for the feet-first plan. TomoDirect™
allows to expand the beam angle on both edges by a max-
imum of 5 leaves each (3.125 cm at isocenter). This ex-
pansion is limited when leaves at the end of the MLC are
already in use. As a precaution against dislocation of the
patient or patient movement, for every plan the maximum
possible beam expansion was chosen.
Treatment plans were analysed according to ICRU 83
[14] including D2 (near-max dose), D98 (near-min dose),
mean and median dose, homogeneity index (difference
between D2 and D98 divided by the median dose), mean
doses of left and right inner lung and treatment time.
For a better understanding of the treatment planning,
we studied the effect of variations of the modulation
factor (MF), pitch, field width of Y-jaws (FW) and dose
grid during optimization for an adult case.
Backup concept
In clinical routine, the translational method was used as
a backup concept so it can be switched to it if a break-
down of the treatment unit occurs. Individual lung
blocks were manufactured for every patient before the
first fraction.
Dosimetric measurements
The following dosimetric studies were performed: (I) Planning
and irradiation of a RANDO™ phantom (Radiology Support
Devices, Inc., Long Beach, USA) containing thermoluminescentTable 2 Constraints of the targets and organs-at-risk
which have to be fulfilled for an accepted plan
Organ Constraints corresponds at 12 Gy
(lung 8 Gy) to
Total body D98 > 90% D near-min > 10.8 Gy
D2 < 110% D near-max < 13.2 Gy
Inner lungs D med < 75% D median < 9 Gy
V prescr dose > 90% V 8 Gy > 90%
Eyes D max < 105% D max < 12,6 Gyrods (TLDs), (II) verification of a planned case with a
Delta4® system (Scandidos AB, Uppsala, Sweden). In clin-
ical routine the following measurements were performed
for every patient: (III) recalculation of planned cases in
a cylindrical solid water phantom (“Cheese phantom”,
TomoTherapy®) and measurements with ion chambers
Exradin® A1SL (Standard Imaging Inc.) in regions repre-
senting lung, mediastinum and leg, (IV) in-vivo dosimetry
with TLDs (ten positions with 3 TLDs each). They are po-
sitioned in different regions, especially in those where a
higher risk of possible dislocations can be expected (shoul-
der, overlap regions).
Patient setup verification
Phantoms and patients were positioned using the MVCT
scanner of the TomoTherapy® system before delivery of
every fraction. The scans were taken from the caudal
edge of the eyes to the pelvis. The images were automatic-
ally fused with the kV planning CT and verified manually
in all views. Besides the position of the patient outline and




All calculated dose plans were in agreement with the de-
fined constraints (Table 3). D near-min (D98) was 11.45
± 0.12 Gy (mean ± S.D.) for the head-first plans and
11.72 ± 0.18 Gy for the feet-first plans, the near-
maximum dose (D2) was 12.94 ± 0.13 Gy for the head-
first plans and 12.78 ± 0.19 Gy for the feet-first plans.
Dmean for the left and right inner lung were 8.73 ±
0.22 Gy and 8.69 ± 0.27 Gy.
The treatment time per fraction was 45.7-68.9 min for
the head first plans and 12.3-16.0 min for the feet-first
plans of the adults (fractional dose 3 Gy).
Variations in the MF, pitch and FW for head-first plans
(fractional dose 3 Gy) with twelve beams and with other-
wise constant parameters yield different dose-volume-
histograms (DVH) and treatment times (see Figure 2). If
the planned modulation factor was between 1.25 and 2
Table 3 DVH results (hf = head-first plan, ff = feet-first plan, HI = homogeneity index = difference between D2 and D98











1 – hf 3 Gy 59.6 11.5 13.1 12.37 0.129 8.68 8.43
2 – hf 3 Gy 68.9 11.4 13.0 12.23 0.131 8.91 8.76
3 – hf 2 Gy 29.1 11.2 12.7 12.13 0.124 8.29 8.22
4 – hf 3 Gy 50.9 11.5 12.9 12.30 0.114 8.76 8.65
4 – ff 3 Gy 13.5 11.4 13.1 12.30 0.138
5 – hf 3 Gy 45.7 11.5 13.0 12.35 0.121 8.64 8.69
5 – ff 3 Gy 12.3 11.8 12.7 12.09 0.074
6 – hf 3 Gy 59.0 11.6 13.0 12.38 0.113 9.03 9.11
6 – ff 3 Gy 14.7 11.8 12.7 12.12 0.074
7 – hf 3 Gy 45.7 11.5 13.0 12.34 0.122 8.69 8.70
7 – ff 3 Gy 16.0 11.8 12.8 12.19 0.082
8 – hf 3 Gy 49.9 11.4 12.8 12.25 0.114 8.86 8.93
8 – ff 3 Gy 13.9 11.8 12.6 12.18 0.066
Range hf 45.7-68.9 (without pat. 3) 11.2-11.5 12.7-13.1 12.13-12.37 0.114-0.131 8.20-9.03 8.22-9.11
Range ff 12.3-16.0 11.4-11.8 12.6-13.1 12.09-12.30 0.066-0.138
Average hf 54.2 (without pat. 3) 11.45 12.94 12.29 0.121 8.73 8.69
Average ff 14.1 11.72 12.78 12.18 0.087
Figure 1 Twelve beams with equally spaced angles were used for the head-first-plan. The beams were expanded (yellow part of the
beam) laterally on both edges by a maximum of 5 leaves each (3,125 cm at isocenter). This expansion is limited if leaves on the end of the MLC
are already used because of the patient size.
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Figure 2 Dose volume histograms of total body (head-first plan), lung and inner lung as a function of modulation factor (MF), pitch
and field width of Y-jaws (FW). Values, if not varied are: MF = 1.5, pitch = 0.25, FW = 2.5 cm.
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Table 4 Results of TLD measurements in the Rando™






dev. >5% dev. >3%
Head and neck 4 −3.47 1.11 0 3
Thorax without
lung
7 −1.19 1.15 0 0
Lung 10 1.11 1.84 0 2
Abdomen 4 −1.40 2.10 0 2
All 25 −0,66 2.26 0 7
Figure 3 Results of a dose measurement of a TBI plan with the dose
truncated below the stomach for this measurement to allow the use of thi
parts of the Delta4®.
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showed an increased homogeneity with increasing MF,
while the treatment time per fraction was also increased
(MF planned 1.25, finally 1.44: 40.8 min, MF = 1.5/1.72:
45.7 min, MF = 2.0/2.26: 60.3 min, MF = 5/5.58: 145 min).
If the planned MF was greater than 2, the dose homogen-
eity was not improved with increasing MF, while the treat-
ment time became longer.
If the pitch changed from 0.25 to 0.5 (MF was 1.5, FW
was 2.5 cm), there were only small differences determin-
able in the DVHs, and treatment times changed only
minimally (45.7 vs. 45.8 min). In some cases we ob-
served fewer hot or cold spots if the pitch was smaller.
Modification of the field width had considerable influ-
ence on the treatment time (FW= 2.5 cm: 45.7 min, FW=verification system Delta4® in the thorax area. The target was
s system without undesired irradiation of the radiosensitive electronic
Figure 4 Dose distribution (in Gy) of a TBI head-first treatment
plan. Isodoses: 14 Gy (red), 13 Gy (orange), 12 Gy (green), 11 Gy
(green), 10 Gy (light blue), 9 – 8 – 6 – 4 – 2 Gy blue (stepwise).
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constant.
A critical point can be the dose grid. It was observed
that differences between the calculated dose distribution
before and after final dose calculation can locally amount
to 1 Gy if the optimization was not performed with the
fine dose grid, which should be taken into account for the
optimization. This is especially important for small organs
with strong maximum criteria as the lens.
Dose verification measurements
Planning and irradiation of a RANDO phantom with
thermoluminescent rods showed a mean deviation of
0.66 ± .2.26% between calculation and measurement
(Table 4). 18 of 25 TLDs showed a deviation smaller
than 3%, no TLD showed a deviation larger than 5%.
The dose measurements with the dose verification sys-
tem Delta4® in the thorax (see Figure 3) showed a me-
dian dose deviation of 1.5%. The dose deviation was less
than 3% for 89% of the diodes in the high-dose area and
in the lung. Figure 3 shows a line dose from the left to
the right side in the thorax.
The measurements with the ion chamber in a cylindrical
phantom (“Cheese phantom”, TomoTherapy®) showed a
mean error in the mediastinum of 1.1 ± 1.5%, in the lung
of 2.2 ± 1.8% and in the leg of 1.8% ± 0.7% of the calcu-
lated dose.
Patient immobilization and setup verification
Patient immobilization and setup verification were well
tolerated. For the correction of set-up errors the main
focus was on a correct positioning of the cranio-thoracic
area (vertebrae, lung). Setup errors in the head area after
correction amounted to 5 mm or less.
Discussion
The introduction of intensity modulated TBI techniques
has the potential to homogenize the dose to the target
and to reduce the prescribed dose on specified organs
(see Figure 4). A comparison with the conventional trans-
lation method with lung blocks reveals a much higher
homogeneity in the target with TomoDirect™ (Figure 5).
Irradiation in prone position is not necessary, which is
more comfortable for the patient.
The limited table motion capacity of the table of both
TomoTherapy® and CT has to be considered carefully.
We decided to start in head-first position, then to turn
the vacuum cushion and subsequently treat feet-first. So
we have two target volumes: one in the head-first CT
beginning from the head and one in the feet-first CT
(legs, feet) with a defined distance to each other. The
definition of two “overlap regions” with an extension of
three cm each enables smooth dose gradients in each
plan to avoid critical overdosage and underdosage. Thecumulative dose in this region was measured in-vivo
with TLDs.
Treatment planning
Treatment plans with a very good dose homogeneity can
be obtained with different parameters.
Our studies showed that the modulation factor (MF)
has the most prominent impact on dose homogeneity
and treatment time especially if it is between 1 and 2. Be-
yond these values, the treatment time is prolonged without
an effect on treatment plans. For that reason the planned
modulation factor should be smaller than 2. A small pitch
can be helpful for patients with a large diameter to avoid
few small underdosage regions near the skin. No note-
worthy differences were seen for smaller patients.
Comparing treatment plans calculated with a field width
of 5 cm and 2.5 cm, the treatment time differs by a factor
Figure 5 Comparison of dose-volume-histograms for the translational method with lung blocks and TomoDirectTM. The DVH of the
treatment plan of the translational technique was calculated with Oncentra, the comparison is done with Oncentra as well.
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We prefer a treatment time of approximately one hour for
adults in this study as a compromise between a lower
mean dose rate in the lung and the patient’s comfort. Be-
cause of the above-named considerations, a MF of 1.5, a
pitch of 0.25, a field width of 2.5 cm and a fine dose grid
already during inverse planning are used now as default
values.
Patient immobilization and setup verification
TomoDirect™ requires a higher accuracy in patient posi-
tioning than conventional methods. On the other hand,
the use of a vacuum cushion and the MVCT option en-
sure a sufficient accuracy.
Because the beams include up to five additional open
leaves at the edges, set-up errors up to 2 cm can be toler-
ated. Therefore no masks for head and neck were used.
Comparison between static and helical tomotherapy
The main difference between static and helical TomoTherapy®
is that with TomoDirect™ the body gets the dose from up
to 12 fixed beams. So it is similar to a linac-based IMRT
but with a very large field length. Taking into account that
for the irradiation of one beam between 3.5 min and
5 min are needed, the irradiation time for single organs
or points in the body is 30–60 min. With helical
TomoTherapy®, the full fractional dose per point is given
in one portion with a duration less than one minute. Ac-
cording to [15] the toxicity to the lung is more dependenton the average dose rate than on the maximum or instant-
aneous dose rate. An irradiation with several beams pro-
longs the treatment time per fraction of the lung and can
be less toxic than one beam, but there is no clinical evi-
dence up to now.
A second point of view is the dose heterogeneity in
circulating blood. Malloy et al. [16] showed that the blood
dose heterogeneity is improved by the use of longer treat-
ment times and reduced dose rates for sequential tech-
niques like IMRT and TomoTherapy®. It is reported
furthermore, that the dose heterogeneity is on the order of
magnitude of + − 10% for a treatment time of 20 min and
a (theoretical) 2 min (125 s) perfusion period, which cor-
responds to heterogeneity values that are typically consid-
ered acceptable when evaluating traditional TBI [16].
Considering these results, dose heterogeneity in circulat-
ing blood cells is improved with TomoDirect™ compared
to helical TomoTherapy® for typical treatment times, per-
fusion rates and cell types.
The third difference are the additional open leaves at the
edges of the beam. In helical mode it is not possible to cre-
ate such a beam expansion. So set-up errors up to 2 cm can
be tolerated and masks for head and neck can be omitted.
Independent of that, a voxel based dose algorithm as
reported in [17] has the potential to implement adaptive
radiotherapy and to improve the robustness for helical
TomoTherapy®.
Finally, the dose distribution is sufficient with both
techniques, perhaps with less hot spots with TomoDirect™.
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umes with helical TomoTherapy®. For most cases we did
not find dose maxima larger than 120% with TomoDirect™.
The near-max dose D2 was between 12.7 and 13.1 Gy for
all cases.
Potential use
TomoDirect™ allows the implementation of organ-specific
dose prescriptions. So the dose to sensitive structures can
be lowered which has the potential to reduce acute and
chronic morbidity. Otherwise it is supposed [18,19] that
“more dose in the target is better” if the biologically effect-
ive doses in lung, kidney and eyes are not increased. So
this technique may allow delivery of higher doses or
dose escalation with limited toxicity to normal critical
structures. Irradiation with simultaneous integrated boost,
e.g. for bone marrow, are in the realm of possibilities for
TBI now.
Conclusion
With the new TomoDirect™ modality, the TomoTherapy®
system combines the conventional translational method
for TBI with the possibilities of IMRT. There are clear ad-
vantages compared to conventional methods which make
it very attractive: excellent homogeneity, dose sparing of
specific organs and comfort can be assumed to be for the
benefit of the patient. The discussion about the “delicate
balance” [18] between the need for aggressive treatment
and limited toxicity can be renewed with the new poten-
tials of TomoDirect™ - for children as well as for adults –
and possibly yield a better clinical outcome in the future.
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